humanized glp-1 receptor knock-in mouse The Obesity Science & Innovation 2025: Generation of GIPR Mice for Obesity and Diabetes Preclinical Generation and characterisation of a

Should I stop semaglutide if a result is abnormal

In the LEADER trial, liraglutide demonstrated cardiovascular benefit, and GLP1RAs have similar effects, aligning with liraglutides anti-atherosclerotic effect

Similar to other chronic diseases, if the treatment for the disease of obesity is stopped, weight regain will likely occur and the health benefits will be diminished [14]

Ganta says she considers her patients specific health profiles before prescribing GLP-1s, especially with older adults who have frailty, dementia, or another geriatric syndrome

The short answer: You can begin with your primary care clinician, a specialist in obesity medicine, or in some cases a telehealth provider

As clinicians, we like solid evidence-based [interventions]. Working holistically GLP-1 agonists, which are more commonly known by popular brand names, Ozempic and Wegovy, are injectable medications that mimic glucagon-like peptide-1, a natural hormone secreted in response to food intake that slows digestion and gives the brain satiety signals